Evaluation of the Safety in the Combination Usage of Cerdelga and Cerezyme in Type III Gaucher Disease Patients and the Efficacy on Soft Tissue Diseases.
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Apr 2019
Price : $35 *
At a glance
- Drugs Eliglustat (Primary) ; Imiglucerase
- Indications Gaucher's disease type III
- Focus Adverse reactions
- 28 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 10 May 2018 New trial record